Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the latest study to show it may rival powerful injections for high-risk patients.
The new pill, called enlicitide, cut levels of bad cholesterol more than 64% in patients who were also taking statins, according to results being presented Monday at the American College of Cardiology meeting in New Orleans and simultaneously published in the group’s medical journal. The drop was significantly greater than the decline with the older Zetia pill, Esperion Therapeutics Inc.’s Nexletol or the combination of the two, Merck said in a statement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.